Insulin sensitizers for women with polycystic ovarian syndrome

References

• Azziz R, Sanchez LA, Knochenhauer ES et al. Androgen excess in women: experience with over 1000 consecutive patients. J. Clin. Endocrinol. Metab.89(2), 453–462 (2004).
   PubMed Web of Science ®Google Scholar
• Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J. Clin. Endocrinol. Metab.93, 162–168 (2008).
   PubMed Web of Science ®Google Scholar
• Stein IF, Leventhal NL. Amenorrhea associated with bilateral polycystic ovaries. Am. J. Obstet. Gynecol.29, 181–191 (1935).
   Google Scholar
• Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Polycystic Ovary Syndrome. Dunaif A, Givens JR, Haseltine FP, Merriam GR (Eds). Blackwell Scientific Publications, Boston, MA, USA 377–384 (1992).
   Google Scholar
• The Rotterdam ESHRE/ASRM. Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril.81, 19–25 (2004).
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM. Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod.19, 41–47 (2004).
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Dewailly D et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J. Clin. Endocrinol. Metab.91, 4237–4245 (2006).
   PubMed Web of Science ®Google Scholar
• Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum. Reprod.9(6), 505–514 (2003).
   Google Scholar
• Azziz R. Definition, Diagnosis and Epidemiology of Polycystic Ovary Syndrome. In: The Polycystic Ovary Syndrome: Current Concepts On Pathogenesis And Clinical Care. Azziz R (Ed.). Springerlink, USA 1–15 (2007).
   Google Scholar
• Carmina E, Legro RS, Stamets K et al. Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum. Reprod.18, 2289–2293 (2003).
   PubMed Web of Science ®Google Scholar
• Hahn S, Tan S, Elsenbruch S et al. Clinical and biochemical characterization of women with polycystic ovary syndrome in North Rhine-Westphalia. Horm. Metab. Res.37, 438–444 (2005).
   Google Scholar
• Pasquali R, Patton L, Diamanti-Kandarakis E, Gambineri A. Role of obesity and adiposity in PCOS. In: The Polycystic Ovary Syndrome: Current Concepts On Pathogenesis And Clinical Care Azziz R (Ed.). Springerlink, USA 85–97 (2007).
   Google Scholar
• DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil. Steril.83, 1454–1460 (2005).
   PubMed Web of Science ®Google Scholar
• Van Santbrink EJ, Hop WC, Fauser BC. Classification of normogonadotropic infertility: polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome. Fertil. Steril.67, 452–458 (1997).
   PubMedGoogle Scholar
• Goodarzi MO. Definition, Diagnosis and Epidemiology of Polycystic Ovary Syndrome. In: The Polycystic Ovary Syndrome: Current Concepts On Pathogenesis And Clinical Care. Azziz R (Ed.). Springerlink, USA 29–42 (2007).
   Google Scholar
• Salehi M, Bravo-Vera R, Sheikh A, Gouller A, Poretsky L. Pathogenesis of polycystic ovary syndrome: what is the role of obesity? Metabolism53(3), 358–376 (2004).
   PubMed Web of Science ®Google Scholar
• Pasquali R, Patton L, Pocognoli P, Cognigni GE, Gambineri A. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome. J. Clin. Endocrinol. Metab.92(11), 4208–4217 (2007).
   PubMed Web of Science ®Google Scholar
• Bremer AA, Miller WL. The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance. Fertil. Steril.89(5), 1039–1048 (2008).
   PubMed Web of Science ®Google Scholar
• Invitti C, De Martin M, Delitala G. Altered morning and nighttime pulsatile corticotropin and cortisol release in polycystic ovary syndrome. Metabolism47, 143–148 (1998).
   PubMed Web of Science ®Google Scholar
• Salehi M, Bravo-Vera R, Sheikh A, Gouller A, Poretsky L. Pathogenesis of polycystic ovary syndrome: what is the role of obesity? Metabolism53, 358–376 (2004).
   PubMed Web of Science ®Google Scholar
• Reaven GM. Obesity, insulin resistance, and cardiovascular disease. Recent Prog. Horm. Res.59, 207–223 (2004).
   PubMedGoogle Scholar
• McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann. Intern. Med.139, 802–809 (2003).
   PubMed Web of Science ®Google Scholar
• McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism53, 495–499 (2004).
   PubMed Web of Science ®Google Scholar
• Asagamia T, Holmesb TH, Reavena G. Differential effects of insulin sensitivity on androgens in obese women with polycystic ovary syndrome or normal ovulation. Metabolism57(10), 1355–1360 (2008).
   Google Scholar
• Baillargeon J-P. The Polycystic Ovary Syndrome: Current Concepts On Pathogenesis And Clinical Care. Azziz R (Ed.). Springerlink, USA 43–68 (2007).
   Google Scholar
• Greenfield JR, Campbell LV. Insulin resistance and obesity. Clin. Dermatol.22(4), 289–295 (2004).
   Google Scholar
• Greisen S, Flyvbjerg A, Ledet T, Ovesen P. Regulation of insulin-like growth factor binding protein secretion by human granulosa luteal cells in a polycystic ovary-like environment. Fertil. Steril.78(1), 162–168 (2002).
   Google Scholar
• Nelson-Degrave VL, Wickenheisser JK, Hendricks KL et al. Alterations in mitogenactivated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome. Mol. Endocrinol.19, 379–390 (2005).
   PubMedGoogle Scholar
• Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocrine30(1), 13–17 (2006).
   PubMed Web of Science ®Google Scholar
• Seto-Young D, Zajac J, Hung-Ching L et al. The role of mitogen-activated protein kinase in insulin and insulin-like growth factor I (IGF-I) signaling cascades for progesterone and IGF-binding protein-1 production in human granulosa cells. J. Clin. Endocrinol. Metab.88, 3385–3391 (2003).
   Google Scholar
• Garcia-Rudaz MC. Amplified and orderly growth hormone secretion characterizes lean adolescents with polycystic ovary syndrome. Eur. J. Endocrinol.147, 207–216 (2002).
   Google Scholar
• Norman RJ, Homan G, Moran L, Noakes M. Lifestyle choices, diet, and insulin sensitizers in polycystic ovary syndrome. Endocrine30(1), 35–43 (2006).
   PubMedGoogle Scholar
• The Practice Committee of the American Society for Reproductive Medicine. Use of insulin sensitizing agents in the treatment of polycystic ovary syndrome. Fertil. Steril.82, S181–S183 (2004).
   PubMed Web of Science ®Google Scholar
• Nestler JE. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil. Steril.77, 209–215 (2002).
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H. Thiazolidinediones. N. Engl. J. Med.351, 1106–1118 (2004).
   PubMed Web of Science ®Google Scholar
• Belli SH, Graffigna MN, Oneto A, Otero P, Schurman L, Levalle OA. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil. Steril.81, 624–629 (2004).
   PubMed Web of Science ®Google Scholar
• Sepilian V, Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J. Clin. Endocrinol. Metab.90, 60–65 (2005).
   PubMed Web of Science ®Google Scholar
• Romualdi D, Guido M, Ciampelli M et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum. Reprod.18, 1210–1218 (2003).
   PubMed Web of Science ®Google Scholar
• Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.89, 3835–3840 (2004).
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in non-obese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil. Steril.82, 893–902 (2004).
   PubMed Web of Science ®Google Scholar
• Ortega-Gonzalez C, Luna S, Hernandez L et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.90, 1360–1365 (2005).
   PubMed Web of Science ®Google Scholar
• Mitwally MF, Witchel SF, Casper RF. Troglitazone: a possible modulator of ovarian steroidogenesis. J. Soc. Gynecol. Investig.9, 163–167 (2002).
   PubMedGoogle Scholar
• Guido M, Romualdi D, Suriano R et al. Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome. Hum. Reprod.19, 534–539 (2004).
   PubMed Web of Science ®Google Scholar
• Pasquali R, Gambineri A. Insulin-sensitizing agents in polycystic ovary syndrome. Eur. J. Endocrinol.14(6), 763–775 (2006).
   Google Scholar
• Marca A, Egbe TO, Morgante G et al. Metformin treatment reduces ovarian cytochrome P-450c17α response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome. Hum. Reprod.15, 21–23 (2000).
   Google Scholar
• Genazzani AD, Lanzoni C, Ricchieri F, Baraldi E, Casarosa E, Jasonni VM. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Gynecol. Endocrinol.23(3), 246–252 (2007).
   Google Scholar
• Seto-Young D, Paliou M, Schlosser J et al. Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J. Clin. Endocrinol. Metab.90(11), 6099–6105 (2005).
   PubMed Web of Science ®Google Scholar
• Seto-Young D, Avtanski D, Strizhevsky M. Interactions among peroxisome proliferator activated receptor-γ, insulin signaling pathways, and steroidogenic acute regulatory protein in human ovarian cells. J. Clin. Endocrinol. Metab.92(6), 2232–2239 (2007).
   Google Scholar
• Lord JM, Flight IHK, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst. Rev.2, CD003053 (2003).
   Google Scholar
• Costello M, Eden J. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil. Steril.79, 1–9 (2003).
   PubMed Web of Science ®Google Scholar
• Kashyap S, Wells GA, Rosenwaks Z. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum. Reprod.19, 2474–2483 (2004).
   PubMed Web of Science ®Google Scholar
• Moll E, Bossuyt PM, Korevaar JC et al. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ332(7556), 1485 (2006).
   PubMed Web of Science ®Google Scholar
• Legro RS, Barnhart HX, Schlaff WD et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N. Engl. J. Med.356, 551–566 (2007).
   PubMed Web of Science ®Google Scholar
• Maciel GAR, Soares JM Jr, Motta ELA et al. Non obese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil. Steril.81, 355–360 (2004).
   PubMed Web of Science ®Google Scholar
• Dewailly D. Obesity and polycystic ovary syndrome: reproductive issues. Bull. Acad. Natl Med.192(4), 659–660 (2008).
   Google Scholar
• Balen A. The Polycystic Ovary Syndrome: Current Concepts On Pathogenesis And Clinical Care. Azziz R (Ed.). Springerlink, USA 100–115 (2007).
   Google Scholar
• Tasdemir S, Ficicioglu C, Yalti S, Gurbuz B, Basaran T, Yildirim G. The effect of metformin treatment to ovarian response in cases with PCOS. Arch. Gynecol. Obstet.269(2), 121–124 (2004).
   PubMedGoogle Scholar
• Haas DA, Carr BR, Attia GR. Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome. Fertil. Steril.79(3), 469–481 (2003).
   PubMedGoogle Scholar
• Kjøtrod SB, von During V, Carlsen SM. Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Hum. Reprod.19, 1315–1322 (2004).
   PubMed Web of Science ®Google Scholar
• Palomba S, Orio F Jr, Nardo LG et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J. Clin. Endocrinol. Metab.89, 4801–4809 (2004).
   PubMed Web of Science ®Google Scholar
• Palomba S, Orio F Jr, Falbo A et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.90, 4068–4074 (2005).
   PubMed Web of Science ®Google Scholar
• Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr. Rev.4, DOI: er.2008-0030v2 (2009) (Epub ahead of print).
   Google Scholar
• Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr. Rev.28, 463–491 (2007).
   PubMed Web of Science ®Google Scholar
• Jansson PA. Endothelial dysfunction in insulin resistance and Type 2 diabetes. J. Int. Med.262, 173–183 (2007).
   PubMed Web of Science ®Google Scholar
• Lakhani K, Hardiman P, Seifalian AM. Intima-media thickness of elastic and muscular arteries of young women with polycystic ovaries. Atherosclerosis175, 353–359 (2004).
   PubMed Web of Science ®Google Scholar
• Lakhani K, Leonard A, Seifalian AM, Hardiman P. Microvascular dysfunction in women with polycystic ovary syndrome. Hum. Reprod.11, 3219–3224 (2005).
   Google Scholar
• Sorensen MB, Franks S, Robertson C, Pennell DJ, Collins P. Severe endothelial dysfunction in young women with polycystic ovary syndrome is only partially explained by known cardiovascular risk factors. Clin. Endocrinol.(Oxford)65, 655–659 (2006).
   PubMed Web of Science ®Google Scholar
• Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr. Rev.24, 302–312 (2006).
   Google Scholar
• Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. Br. J. Obstet. Gynaecol.113, 1148–1159 (2006).
   Google Scholar
• Diamanti-Kandarakis E, Alexandraki K, Protogerou A et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur. J. Endocrinol.152, 749–756 (2005).
   PubMed Web of Science ®Google Scholar
• Romualdi D, Costantini B, Selvaggi L et al. Metformin improves endothelial function in normoinsulinemic PCOS patients: a new prospective. Hum. Reprod.23(9), 2127–2133 (2008).
   PubMed Web of Science ®Google Scholar
• Mellbin LG, Malmberg K, Norhammar A, Wedel H, Rydén L. The impact of glucose lowering treatment on long-term prognosis in patients with Type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur. Heart J.29, 166–176 (2008).
   PubMed Web of Science ®Google Scholar
• Dunaif A. Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome – a reappraisal. Nat. Clin. Pract. Endocrinol. Metab.4, 272–283 (2008).
   Google Scholar
• Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J. Clin. Endocrinol. Metab.90, 3236–3242 (2005).
   PubMed Web of Science ®Google Scholar
• Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. Position statement: glucose intolerance in polycystic ovary syndrome a position statement of the Androgen. Excess Society. J. Clin. Endocrinol. Metab.92, 4546–4556 (2007).
   PubMed Web of Science ®Google Scholar
• Chen M-J, Yang W-S, Yang J-H, Chen C-L, Ho H-N, Yang Y-S. Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome. Hypertension49, 1442–1447 (2007).
   PubMed Web of Science ®Google Scholar
• Elting MW, Korsen TJM, Bezemer PD, Schoemaker J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum. Reprod.16, 556–560 (2001).
   PubMed Web of Science ®Google Scholar
• Wang X, Jia X, Chang T, Desai K, Wu L. Attenuation of hypertension development by scavenging methylglyoxal in fructose-treated rats. J. Hypertens.26, 765–772 (2008).
   PubMedGoogle Scholar
• Helvaci MR, Kaya H, Borazan A, Ozer C, Seyhanli M, Yalcin A. Metformin and parameters of physical health. Intern. Med.47, 697–703 (2008).
   Google Scholar
• Komajda M, Curtis P, Hanefeld M et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with Type 2 diabetes: a randomized controlled trial. Cardiovasc. Diabetol.7, 10 (2008).
   Google Scholar
• Derosa G, Fogari E, Cicero AF et al. Blood pressure control and inflammatory markers in Type-2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens. Res.30, 387–394 (2007).
   PubMed Web of Science ®Google Scholar
• Hoffman LK, Ehrmann DA. Cardiometabolic features of polycystic ovary syndrome. Nat. Clin. Pract. Endocrinol. Metab.4, 215–222 (2008).
   PubMedGoogle Scholar
• Rizzo M, Berneis K, Carmina E, Rini GB. How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome? Am. J. Obstet. Gynecol.198(28), e1–e5 (2008).
   Google Scholar
• Ng EH, Wat NM, Ho PC. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Hum. Reprod.16, 1625–1631 (2001).
   PubMed Web of Science ®Google Scholar
• Palomba S, Orio F Jr, Falbo A, Russo T, Tolino A, Zullo F. Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome. Fertil. Steril.84, 761–765 (2005).
   Google Scholar
• Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int. J. Obes. Relat. Metab. Disord.28, 1357–1364 (2004).
   PubMed Web of Science ®Google Scholar
• He G, Pedersen SB, Bruun JM, Lihn AS, Richelsen B. Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor-1 production in human adipose tissue in vitro. Horm. Metab. Res.35, 18–23 (2003).
   PubMed Web of Science ®Google Scholar
• Lund SS, Tarnow L, Stehouwer CD. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with Type 2 diabetes. Eur. J. Endocrinol.158, 631–641 (2008).
   PubMed Web of Science ®Google Scholar
• Dandona P, Aljada A, Ghanim H et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J. Clin. Endocrinol. Metab.89, 5043–5047 (2004).
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Paterakis T, Alexandraki K et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum. Reprod.21, 1426–1431 (2006).
   PubMed Web of Science ®Google Scholar
• Orio F Jr, Palomba S, Cascella T et al. The increase of leukocyte as a new marker of low grade chronic inflammation and early cardiovascular risk in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab.90, 2–5 (2005).
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation106, 3143–3421 (2002).
   PubMed Web of Science ®Google Scholar
• Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet. Gynecol.106, 131–137 (2005).
   PubMed Web of Science ®Google Scholar
• Patel AA, Bloomgarden ZT, Futterweit W. Premicroalbuminuria in women with polycystic ovary syndrome: a metabolic risk marker. Endocr. Pract.14, 193–200 (2008).
   PubMedGoogle Scholar